PDCD1 and head and neck squamous cell carcinoma: Recent work on antibodies targeting PD-1 in advanced melanoma has yielded encouraging improvement in survival (28) and clinical trials are currently investigating the efficacy of anti-PD-1 and anti-PD-L1 monoclonal antibodies in recurrent and/or metastatic HNSCC (30–32).